[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-risk-patients-with-pancreatic-exocrine-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-risk-patients-with-pancreatic-exocrine-insufficiency":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100647496","phase-4-a-multicenter-clinical-study-on-protein-absorption-efficiency-in-patients-with-pancreatic-exocrine-insufficiency-in-the-icu-100647496",false,"NCT07709611","A Multicenter Clinical Study on Protein Absorption Efficiency in Patients With Pancreatic Exocrine Insufficiency in the ICU","Comparison of Protein Absorption Efficiency Between Peptide and Whole Protein Enteral Nutrition Preparations in High-risk Groups With Pancreatic Exocrine Insufficiency in the ICU","Inclusion Criteria:\n\n* Age≥ 18 years old, no gender restriction;\n* Meet the criteria for high-risk groups for PEI;\n* AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria;\n* Estimated duration of enteral nutrition support therapy: ≥7 days;\n* The subject or their legally authorized family member must sign the informed consent form\n\nExclusion Criteria:\n\n* Patients who have been clearly diagnosed with PEI or chronic persistent PEI;\n* Patients who have contraindications to enteral nutrition therapy;\n* Patients with severely impaired liver or kidney function;\n* Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia;\n* Patients who have received pancreatic enzyme replacement therapy or taken any medications that may affect protein absorption within 7 days prior to enrollment;\n* Patients for whom the expected length of ICU stay is less than 7 days;\n* Pregnant or lactating women, as well as patients with mental illnesses;\n* Patients who are allergic to any component of the study medication.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The goal of this clinical trial is to systematically evaluate whether peptide-type enteral nutrition (EN) formulations improve protein uptake efficiency in high-risk groups at ICU PEI, using targeted amino acid metabolomics and gut microbiota co-metabolomics as core quantitative indicators.\n\nResearchers will compare protein absorption efficiency of short-chain peptide and complete protein enteral nutrition formulas in high-risk populations for PEI in the ICU\n\nParticipants will:\n\nEnteral nutrition was administered for ICU critically ill patients with high-risk factors for PEI",[26,27],"High-risk Patients With Pancreatic Exocrine Insufficiency","Enteral Nutrition Feeding",[29,30,31,32],"Pancreatic exocrine Insufficiency","Enteral nutrition","Peptide-based","Absorption efficiency","NOT_YET_RECRUITING","2026-07-13",{"date":36,"type":37},"2026-07-16","ACTUAL",{"date":39,"type":20},"2026-07-01",{"date":41,"type":20},"2027-12-31",{"name":43,"class":44},"Shanghai 10th People's Hospital","OTHER"]